TTrialPathMatch Me to Trials
← Back to trials
RecruitingHigh Risk CancerPancreatic Cancer

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Eligible age

40+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

You may qualify if…

  • ✓ Cohort A: Must fall into one of the three categories defined as high risk of developing pancreatic cancer and are undergoing pancreatic surveillance AND 2) have documented radiographic evidence of a pancreatic abnormality such as a pancreatic cyst.
  • ✓ High Risk Group 1 (familial pancreatic cancer relatives):
  • ✓ \>/=55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and
  • ✓ Come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and
  • ✓ Have a first-degree relationship with at least one of the relatives with pancreatic cancer.
  • ✓ If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened.
  • ✓ High Risk Group 2 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~10% or higher):
  • ✓ \>/=40 years old and the Patient is a carrier of FAMMM (p16/CDKN2A) mutation regardless of family pancreas cancer history.

You may not qualify if…

  • ✕ If expected to require any other form of systemic or localized antineoplastic therapy while on study.
  • ✕ Within 4 weeks prior to first dose of study drug.
  • ✕ o Any systemic or topical corticosteroids at immunosuppressive agents.
  • ✕ Within 4 weeks prior to first dose of study drug.
  • ✕ Any investigational device.
  • ✕ Has received a live vaccine.
  • ✕ Received any allergen hyposensitization therapy.
  • ✕ Any major surgery.

Where it's recruiting

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT05013216 · last updated 2025-12-03

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk o · TrialPath